Vermeire S, Sands BE, Tilg H, Tulassay Z, et al. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol 2022 Sep 5. pii: S2468-1253(22)00233.
PMID: 36075249